Oluwatosin Olaiya

Dr. Oluwatosin Olaiya

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
GMGaurav Mathur
Gaurav Mathur
JDJoseph Domachowske
Joseph Domachowske
MGMaria Gabriela Graña
Maria Gabriela Graña
RLReena Ladak
Reena Ladak
JLJoanne Langley
Joanne Langley
RVRodolfo Villena
Rodolfo Villena
Background: Invasive meningococcal disease (IMD) is an uncommon but potentially life-threatening condition, resulting in life-long sequelae or death in up to 20% of cases. Most IMD cases are caused by Neisseria meningitidis serogroups (Men) A, B, C, W, X, and Y. The highest IMD incidence is among children < 5 years of age (YOA). We reviewed IMD epidemiology data and existing national immunization programs (NIP) in the Americas and identify unmet needs to decrease IMD burden in young children. Methods: Using national surveillance data and published literature from 2006 to 2024, we evaluated the IMD burden and national vaccination strategies for children < 5 YOA in the Americas, focusing on Canada, the United States, Brazil, Chile, Argentina. Results: The highest IMD incidence was among infants, followed by children 1–4 YOA, with MenB infections predominating in both age groups. Chile has both MenACWY (2014) and MenB (2023) infant vaccination in its NIP. Argentina and Brazil’s NIPs include MenACWY (2017) and MenC (2010) vaccinations for infants, respectively. In Canada, MenC (2002) vaccination is recommended at 1 YOA (replaced by MenACWY in 2024 in Manitoba); MenB vaccination is selectively recommended. In each country, the incidence of IMD caused by vaccine-preventable serogroups decreased following the introduction of the respective meningococcal vaccination in the NIP. Conclusions: Comprehensive meningococcal vaccination programs in the Americas have the potential to reduce the IMD burden in children < 5 YOA. National recommendations and NIPs could reduce IMD burden by offering equitable access to protection against IMD, aligning with the WHO roadmap to defeat meningitis by 2030.

19 February 2025 in Journal of Adolescent Health
Verified
Journal Article
Open access
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
DCDiana E. Clements
Diana E. Clements
OOOluwatosin Olaiya
Oluwatosin Olaiya
GMGary S. Marshall
Gary S. Marshall
The United States Advisory Committee on Immunization Practices recommends routine vaccination against meningococcal serogroups A, C, W, and Y for all aged 11-12 years (with a booster dose for age 16 years) and vaccination against meningococcal serogroup B (MenB) for ages 16-23 years under shared clinical decision-making (SCDM). Considering the Advisory Committee on Immunization Practices' ongoing revision of the adolescent meningococcal vaccine schedule, it is important to capture the perspectives of key stakeholders (adolescents and young adults, parents, and health-care providers) in order to understand barriers to meningococcal vaccination. We conducted a targeted literature search and narrative review of survey-based studies to consolidate available evidence on knowledge, attitudes, and practices among these stakeholders since the MenB recommendation in 2015. Our study identified persistent knowledge gaps regarding invasive meningococcal disease (IMD) risks, MenB, and SCDM among patients, parents, and health-care providers, suggesting that SCDM may not be consistently taking place. Simplifying the meningococcal vaccination schedule may more broadly protect United States adolescents and young adults against IMD and should be accompanied by efforts to increase knowledge and awareness among patients and parents regarding IMD and MenB.

11 September 2024 in Expert Review of Vaccines
Verified
Journal Article
Open access
DCDiana E. Clements
Diana E. Clements
OOOluwatosin Olaiya
Oluwatosin Olaiya
CBCindy Burman
Cindy Burman
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
WSWoo-Yun Sohn
Woo-Yun Sohn
JCJames H. Conway
James H. Conway
In 2005, the United States Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y (MenACWY) for all 11-12-year-olds, as well as 2-10-year-olds at high risk. In 2010, a booster dose was recommended for all 16-year-olds, as well as for high-risk patients every 3-5 years. In 2015, optional (as opposed to routine) vaccination against meningococcal serogroup B (MenB) at the preferred age of 16-18 years was recommended (Category B, later changed to shared clinical decision-making). In 2023, a vaccine (MenABCWY) against the 5 serogroups primarily responsible for IMD in the US became available. This review summarizes the evolution of public policy that led to each milestone vaccine recommendation, reviews epidemiologic data published following the recommendations, and discusses the current state of meningococcal immunization policy. The use of MenABCWY has the potential to consolidate policy, improve coverage rates for the 5 serogroups, address disparities in vaccination coverage, and simplify vaccine delivery.

3 August 2025 in Current Medical Research and Opinion
Verified
Journal Article
Open access
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
JMJasjit Multani
Jasjit Multani
ZZZifan Zhou
Zifan Zhou
QPQueenie Paltanwale
Queenie Paltanwale
OOOluwatosin Olaiya
Oluwatosin Olaiya
CCChi-Chang Chen
Chi-Chang Chen
Several vaccines are recommended for 16-23-year-olds in the United States, but coverage varies widely across these vaccines. Previous studies have indicated that routine healthcare visits are associated with vaccination uptake. This study aimed to describe healthcare visit patterns among 16-23-year-olds to identify challenges and inform opportunities to reach adolescents and young adults for vaccination. A descriptive, retrospective database analysis was conducted of commercially insured and Medicaid-insured 16-23-year-olds from 2019-2022 using IQVIA's PharMetrics® Plus claims database and open-source Longitudinal Prescription/Medical claims databases. The proportion of 16-23-year-olds with healthcare provider (HCP) visits, visit types, provider types involved, visits including vaccination, and specific vaccines delivered were analyzed. In 2022, 68.2% of commercially insured 16-23-year-olds had ≥1 HCP visit. Most commercially insured and Medicaid-insured individuals with ≥1 HCP visit had sick visits (72.9-80.6%). The proportion of individuals with preventative visits was lower as age increased (commercially insured: 73.2% at 16, 67.4% at 18, 56.3% at 19, and 45.3% at 23 years). Lower proportions of individuals with preventative visits with increasing age were also seen among Medicaid-insured individuals, ranging from 53.7% at 16 years to 28.0% at 23 years. Among 16-18-year-olds with ≥1 HCP or pharmacy visit in 2022, 52.6% in the commercial cohort and 33.0% in the Medicaid cohort had visits that involved vaccination; for 19-23-year-olds, these proportions were 34.5% and 25.6%, respectively. Vaccination rates by vaccine type were largely aligned with the ages specified by recommendations, but nonetheless were low. Approximately one-third of commercially insured 16-23-year-olds did not have an annual HCP visit, and among commercially insured and Medicaid-insured individuals who did have visits, a substantial proportion did not have preventative visits; this proportion was higher with increasing age. The proportions of visits with vaccination were particularly low for 19-23-year-olds. Targeted interventions to promote routine visits, including framing these as opportunities for immunization, may help to increase vaccination uptake; based on the findings of this analysis, these efforts should consider age-specific shifts in health-seeking behaviors.

3 June 2025 in Current Medical Research and Opinion
Verified
Journal Article
Open access
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
JMJasjit Multani
Jasjit Multani
ZZZifan Zhou
Zifan Zhou
QPQueenie Paltanwale
Queenie Paltanwale
OOOluwatosin Olaiya
Oluwatosin Olaiya
CCChi-Chang Chen
Chi-Chang Chen
In the United States (US), meningococcal serogroup B (MenB) vaccination is currently recommended under shared clinical decision-making for 16-23-year-olds to prevent invasive meningococcal disease; the MenB vaccine may be co-administered with other vaccines recommended for this age group. A retrospective analysis of two US health insurance claims databases was conducted to estimate the proportion of commercially insured and Medicaid-insured 16-23-year-olds with potential missed opportunities for MenB vaccine series initiation via co-administration. Potential missed opportunities were defined as visits with healthcare providers during which other recommended vaccines (MenACWY, Tdap, HPV, influenza, and/or COVID-19) were administered, but not the initial MenB vaccine dose. In 2022, 74.5% of commercially insured and 67.1% of Medicaid-insured 16-23-year-olds had potential missed opportunities for MenB vaccination initiation via co-administration. The proportion of missed opportunities was higher among 19-23-year-olds (versus 16-18-year-olds) and lower for visits with pediatricians (versus internists or general practitioners/family physicians). The most frequently co-administered vaccine was the MenACWY vaccine. Many 16-23-year-olds had potential missed opportunities for MenB series initiation via co-administration. Increasing awareness of the opportunity to initiate the MenB series via co-administration may improve meningococcal vaccination coverage in the United States.

21 September 2026 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
OHOscar Herrera-Restrepo
Oscar Herrera-Restrepo
EPElizabeth Packnett
Elizabeth Packnett
MRMegan Richards
Megan Richards
EKElise Kuylen
Elise Kuylen
OOOluwatosin Olaiya
Oluwatosin Olaiya
AAAndrew G. Allmon
Andrew G. Allmon
Background/Objective Although uncommon, invasive meningococcal disease (IMD) is a serious and life-threatening illness. In the United States (US), incidence is highest among infants aged <1 year, but research characterizing pediatric IMD burden is limited. This study aimed to evaluate health outcomes and economic burden (healthcare resource utilization [HCRU] and costs [associated with health outcomes and HCRU]) in US individuals aged <11 years with IMD and without IMD, and their caregivers, from the patient and payer (commercial and Medicaid insurance) perspective. Methods Retrospective claims analysis utilizing real-world data (1/1/2005–12/31/2022) from the MarketScan® Commercial and Multi-State Medicaid Databases compared health outcomes, HCRU (e.g., inpatient and outpatient admissions, surgical procedures, pharmacy claims), and costs (associated with health outcomes and HCRU) in commercially and Medicaid-insured infants (aged <1 year), toddlers (aged 1–4 years), and children (aged 5–10 years) with IMD versus those without IMD (matched 1:5), and their caregivers. Length of follow-up was variable, divided into acute/post-acute phases for individuals with IMD. Results Infants, toddlers, and children with IMD versus without IMD generally experienced more negative health outcomes and HCRU, and higher associated costs. Common health outcomes among infants with IMD included neurological, physical, and neurodevelopmental/mental health disorders. In the commercially insured cohort, infants with IMD had more inpatient admissions, specialist office visits, and surgical procedures than those without IMD. In the Medicaid-insured cohort, HCRU was higher for infants with IMD versus without IMD. Costs associated with health outcomes and HCRU were higher for infants with IMD versus those without IMD, regardless of insurance cohort. Health outcomes, HCRU, and HCRU-associated costs did not differ for caregivers to individuals with IMD versus without IMD. Conclusion In this retrospective claims analysis from a dual US patient and payer perspective, infants, toddlers, and children with IMD experienced substantial negative health outcomes and economic burden, regardless of insurance status. Preventive interventions in childhood may lessen the impact of IMD on individuals, families, and healthcare systems.